DNA repair after irradiation in glioma cells and normal human astrocytes.
We examined DNA damage responses and repair in four human glioma cell lines (A7, U87, T98G, and U373) and normal human astrocytes (NHAs) after clinically relevant radiation doses to establish whether we could identify differences among them that might suggest new approaches to selective radiosensitization. We used phosphorylation of histone H2AX visualized by immunocytochemistry to assess DNA double-strand break (DSB) formation and resolution. Fluorescence immunocytochemistry was used to visualize and quantify repair foci. Western blotting was used to quantify repair protein levels in the different cell lines before and after irradiation and during different cell cycle phases. Mitotic labeling was used to measure cell cycle parameters after irradiation. We found that the glioma cell lines repaired DSBs more slowly and less effectively than did NHAs in the clinically relevant dose range, as assessed by induction and resolution of H2AX phosphorylation, and this was most marked in the three TP53-mutated cell lines (T98G, A7, and U373). The glioma cells also expressed relatively high repair-protein levels compared with NHAs that were not altered by irradiation. High levels of the repair protein Rad51 in these cells persisted throughout the cell cycle, and a marked increase in Rad51 foci formation, which was not restricted to cells in G2/S phase, occurred at early time points after irradiation. TP53-mutated glioma cell lines demonstrated a very prominent dose-responsive G2 checkpoint and were sensitized to radiation by caffeine, which inhibits G2/S phase checkpoint activation. In conclusion, DNA repair events differed in these four glioma cell lines compared with NHAs. In particular, the three TP53-mutated glioma cell lines exhibited markedly increased Rad51 protein levels and marked, dose-dependent Rad51 foci formation after low radiation doses. This suggests that agents that disrupt Rad51-dependent repair or prevent G2 checkpoint activation may selectively sensitize these cells.
Short
Susan C
SC
Department of Oncology, University College London, 250 Euston Rd., London NW1 2PG, UK. s.short@ucl.ac.uk
Martindale
Christine
C
Bourne
Sara
S
Brand
Geoff
G
Woodcock
Mick
M
Johnston
Peter
P
D001253:Astrocytes / Q000528:radiation effects*; D015153:Blotting, Western; D002453:Cell Cycle / Q000235:genetics / Q000528:radiation effects; D045744:Cell Line, Tumor; D053903:DNA Breaks, Double-Stranded / Q000528:radiation effects*; D004260:DNA Repair / Q000235:genetics* / Q000528:radiation effects*; D004307:Dose-Response Relationship, Radiation; D005455:Fluorescent Antibody Technique; D005910:Glioma / Q000235:genetics*; D006801:Humans; D051135:Rad51 Recombinase / Q000096:biosynthesis / Q000528:radiation effects; D011836:Radiation Tolerance / Q000502:physiology*
D051135:Rad51 Recombinase
J Cell Biol. 2005 Aug 1;170(3):341-7
16061690
Nature. 2005 Mar 31;434(7033):598-604
15800615
Cancer Lett. 2005 Nov 18;229(2):171-9
16129552
Br J Cancer. 2005 Oct 31;93(9):1011-8
16249792
Nature. 2006 Jan 26;439(7075):497-501
16299494
Int J Cancer. 2006 Dec 15;119(12):2784-94
17019715
Am J Pathol. 2007 May;170(5):1445-53
17456751
J Neurosurg. 1999 Dec;91(6):997-1004
10584846
Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1109-15
10613302
Int J Radiat Biol. 1999 Dec;75(12):1589-95
10622265
Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):779-84
10837964
Curr Biol. 2000 Jul 27-Aug 10;10(15):886-95
10959836
Cancer Res. 2002 Jan 1;62(1):219-25
11782381
Cancer Res. 2003 May 15;63(10):2596-605
12750285
Nat Cell Biol. 2003 Jul;5(7):675-9
12792649
Toxicology. 2003 Nov 15;193(1-2):91-109
14599770
Cancer Res. 2003 Nov 1;63(21):7377-83
14612536
DNA Repair (Amst). 2004 Feb 3;3(2):113-20
14706344
Cancer Res. 2005 May 15;65(10):4368-75
15899829
Mutat Res. 2005 Jul 1;574(1-2):22-33
15914204
Clin Cancer Res. 2005 Jun 15;11(12):4444-50
15958629
J Biol Chem. 2004 Apr 9;279(15):15402-10
14744854
J Mol Biol. 2004 Feb 20;336(3):639-54
15095978
Science. 1995 Feb 24;267(5201):1183-5
7855602
Oncol Res. 1994;6(10-11):509-18
7620219
Mol Gen Genet. 1996 Apr 24;251(1):1-12
8628240
Anticancer Drugs. 1997 Jan;8(1):92-7
9147618
J Biol Chem. 1998 Mar 6;273(10):5858-68
9488723
Biochem Biophys Res Commun. 1998 Apr 17;245(2):319-24
9571148
Nucleic Acids Res. 1998 Jun 15;26(12):2859-64
9611228
Int J Radiat Biol. 1999 Jul;75(7):847-55
10489896
Am J Clin Oncol. 2005 Feb;28(1):43-50
15685034
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
N Engl J Med. 2005 Mar 10;352(10):997-1003
15758010
Radiat Res. 2005 Sep;164(3):292-302
16137202